Differentiating acute myeloid leukemia (AML) patients with high risk of aggressive disease from those at lower risk presents a significant challenge. Accuracy in predicting the disease course requires the use of multiple prognostic markers, and new markers are available to better stratify some patients. NeoGenomics Laboratories will host a live Webinar, “Updates on Personalized Medicine: Testing Strategies in Acute Myeloid Leukemia,” on Thursday, December 13, at 2 pm EST, that will cover this topic.
During the webinar, Sally Agersborg, MD, PhD, medical director at NeoGenomics, Irvine, Calif, will describe the roles of cytogenetics, FISH, and molecular testing in the diagnosis and risk stratification of patients with AML. Learning objectives for the Webinar include:
• Brief review of diagnosis of AML
• Review established and new prognostic factors in AML
• Predict clinical course of AML